Introduction {#S1}
============

Noise-induced hearing loss (NHIL) is a significant source of hearing loss in industrialized countries [@R01]. Currently, prevention of NIHL focuses on the use of hearing protecting devices, frequent hearing screening for at risk populations and education on the causes of hearing loss [@R02] [@R03].

Recently, research on the cellular bases of NIHL has led to new avenues for protection through prophylactic drugs. Although in experimental animal models several compounds have shown a protective effect in NIHL [@R04]^-^[@R07], only limited data are available in humans [@R08] [@R09].

Noise exposure causes a broad set of physical changes in the major cellular system of the cochlea that lead to temporary threshold shift (TTS) and permanent threshold shift (PTS) [@R04]. The reversible nature of TTS indicates that the underlying mechanisms associated with hearing loss are most probably of a metabolic nature [@R04] [@R08] [@R10] [@R11].

The generators of this oxidative stress likely include acoustically-induced ischaemia reperfusion, glutamate excitotoxicity and an increase in mitochondrial free radical production due to higher metabolic demand as well as through less efficient energy production due to mitochondrial damage [@R12]^-^[@R14].

Several studies have shown that during and after noise exposure reactive oxygen species (ROS), reactive nitrogen species (RNS) and lipid peroxides all increase [@R04] [@R05]. Yamane et al. [@R15] showed an increase of ROS in marginal cells of stria vascularis, while Nicotera et al. [@R16] were able to localize ROS within outer hair cells (OHC) after noise exposure. Furthermore, Ciorba et al. [@R17] provided evidence, by spectrophotometric analyses, of the presence and production of superoxide in inner ear perilymph of human subjects affected by profound hearing loss and treated with cochlear implantation.

The origin of increased ROS into the cochlea is somewhat speculative. However, the increased energy demand induced by the noise exposure may lead to the use of large amount of oxygen and the formation of peroxide as a byproduct of phosphorylation [@R18]. In addition, noise exposure decreases cochlear blood flow, and its reduction is associated with increased ROS formation [@R04].

Several molecules with antioxidant and scavenging properties including α-tocopherol [@R19]^-^[@R21], idebenone [@R22] [@R23], the water-soluble formulation of coenzyme Q10 [@R24] [@R25], glutathione [@R26], N acetylcysteine [@R27], D-methionine [@R28], ferulic acid (FA, 4-hydroxy 3-methoxycinnamic acid) [@R29] [@R30] have been tested for their ability to reduce oxidative stress-induced hair cell death after intense sound exposure in animals.

Alpha-lipoic acid (ALA), an essential cofactor in mitochondrial enzymes, is a novel biological antioxidant and a potent free radical scavenger [@R31]^-^[@R33]. In animal models, ALA has been shown to protect from both age-induced and cisplatin-induced hearing loss [@R34] [@R35]. The aim of this study was to evaluate the effects of ALA on reversible cochlear alterations using a TTS model in humans.

Materials and methods {#S2}
=====================

A total of 30 volunteers served as subjects were randomly divided into three groups. Mean age was 23.9 years (range 20-30 years). Group A subjects were only exposed to noise, Group B subjects were exposed to noise 1 hour after assumption of 600 mg of ALA (Alfa Wassermann S.p.A., Alanno-PE, Italy) and group C subjects were exposed to noise after 10 days of oral daily assumption of 600 mg of ALA. All subjects signed an informed consent and the drug was kindly provided by Alfa Wassermann S.p.A. The study was approved by the Local Review Board.

Subjects {#S2a}
--------

There were 15 males and 15 females. Subject selection was based on age (20-30 years old) and hearing level (mean threshold for frequencies from 0.5 to 8 kHz better than 20 dB HL). All subjects were carefully screened for negative history of otological disease, noise exposure, ototoxic drugs, metabolic disease associated with hearing loss and family history of hearing loss.

Auditory threshold and otoacoustic emissions measurement {#S2b}
--------------------------------------------------------

Pure tone audiometry was performed in a soundproof cabin using pure tones (250 msec duration, 25 msec rise/ fall time, 50% duty cycle) at octave frequencies from 125 Hz to 8000 Hz with a maximum intensity of 120 dB SPL with an Amplaid 319 audiometer.

TEOAEs were recorded for click stimulation. Clicks were generated by very short electrical pulses (\< 50 μsec) with a wideband spectrum using an ILOV 6 system in the standard non-linear mode. The click level was 0.3 Pa in the ear canal. The intrameatal stimulus intensity was measured directly in the outer auditory canal and was adjusted by the software. The noise rejection level was set at 4.6 mPa corresponding to 47.3 dB SPL. The spectrum analyzer was triggered at 4 msec after the stimulus presentation to avoid acoustic ringing of the input stimuli, and the temporal window was set at 20 msec. 260 averages were recorded. TEOAEs were considered present when the wave reproducibility was greater than 70%. All recordings were performed in a soundproof booth.

Noise exposure and drug assumption {#S2c}
----------------------------------

Subjects were randomly assigned to three groups. Group A (10 subjects) was exposed to a 90 dB HL 3 kHz pure tone for 10 min. Group B (10 subjects) was exposed to a 90 dB HL 3 kHz pure tone 1 hour after the oral assumption of 600 mg of ALA. Group C (10 subjects) was exposed to a 90 dB HL 3 kHz pure tone for 10 min following 10 days of 600 mg ALA. In all subjects, the right ear was exposed to noise.

The high frequency pure tone was generated by an Amplaid 319 audiometer and was delivered by Peltor H7A earphones.

The TTS value was measured at 3, 4 and 6 kHz 2 minutes (TTS~2~) after the end of the exposure. The thresholds for the 3, 4 and 6 kHz tones were measured in the test ear using a 2 dB down-1 dB up tracking method. The TTS~2~ value was the difference between pre and post exposure thresholds. TEOAEs were also recorded at the end of the noise exposure after the threshold measurements.

Statistical analysis {#S2d}
--------------------

ANOV As were used to compare hearing levels, TTS and TEOAEs between the three groups, and values of p \< 0.05 were considered significant. A post-hoc analysis was performed to compare the three groups.

Results {#S3}
=======

The mean pre-exposure thresholds and TTS2 (with standard deviation-SD) for each group are reported in [Table I](#T1){ref-type="table"}. Mean pre and post-exposure TEOAEs amplitudes and reproducibility are reported in [Table II](#T2){ref-type="table"}. Mean threshold pre noise exposure for Group A was -0.9 ± 3.5 dB HL at 3 kHz, -2.8 ± 4.9 dB HL at 4 kHz and 9.5 ± 5.2 dB HL at 6 kHz. Mean threshold for Group B was 1.5 ± 5.4 dB HL at 3 kHz, -2.4 ± 4.9 dB HL at 4 kHz and 4.8 ± 5.9 dB HL at 6 kHz. Mean threshold pre noise exposure for Group C was 5.2 ± 8.4 dB HL at 3 kHz, -0.1 ± 6.5 dB HL at 4 kHz and 8.6 ± 6.5 dB HL at 6 kHz. TTS2 post noise exposure was 5.8 ± 4.5 dB HL at 3 kHz, 10.4 ± 7.9 dB HL at 4 kHz and 15.6 ± 7.3 dB HL at 6 kHz for Group A. TTS2 post noise exposure for Group B was 6.5 ± 3.7 dB HL at 3 kHz, 11.7 ± 4.2 dB HL at 4 kHz and 14.1 ± 5.6dB HL at 6 kHz. In Group C, it was respectively 4.9 ± 6.1 dB HL at 3 kHz, 10.9 ± 6.5 dB HL at 4 kHz and 7.3 ± 7.6dB HL at 6 kHz. TEOAEs mean amplitude measured pre-noise exposure was 16.8 ± 4.3 dB SPL for Group A, 16.6 ± 2.9 dB SPL for Group B and 15.8 ± 4.9 dB SPL for Group C. After noise exposure their change was, respectively, 0.7 ± 1.17, 1 ± 1 and -0.2 ± 0.96 dB SPL.

###### 

Pre-exposure thresholds and TTS2 in the three groups. Mean values and standard deviation (SD) are shown. ANOVA test was used to compare groups.

            Threshold 3 kHz pre   Threshold 4 kHz pre   Threshold 6 kHz pre   TTS2 3 kHz   TTS2 4 kHz   TTS2 6 kHz                                   
  --------- --------------------- --------------------- --------------------- ------------ ------------ ------------ ----- ----- ------ ----- ------ -----
  Group A   -0.9                  3.5                   -2.8                  4.9          9.5          5.2          5.8   4.5   10.4   7.9   15.6   7.3
  Group B   1.5                   5.4                   -2.4                  4.9          4.8          5.9          6.5   3.7   11.7   4.2   14.1   5.6
  Group C   5.2                   8.4                   -0.1                  6.5          8.6          6.5          4.9   6.1   10.9   6.5   7.3    7.6
  p         0.1007                0.424                 0.1886                0.129        0.521        0.004                                        

###### 

Pre-exposure TEOAEs amplitudes and standard deviations (SD) pre-exposure and TEOAEs change after noise exposure are reported. ANOVA test was used to compare groups.

            TEOAEs pre exposure   TEOAEs change after noise exposure          
  --------- --------------------- ------------------------------------ ------ ------
  Group A   16.8                  4.3                                  0.7    1.17
  Group B   16.6                  2.9                                  1      1
  Group C   15.8                  4.9                                  -0.2   0.96
  p         0.835                 0.0278                                      

Statistical analysis showed that prior to exposure hearing thresholds and TEOAEs amplitude did not differ significantly between the three groups. After exposure, 4 and 6 kHz were the most affected frequencies in all groups ([Table I](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}). Statistical analysis showed that TTS~2~ at 3 and 4 kHz was not significantly different in the three groups, but only for 6 kHz (p = 0.004). At 6 kHz, Group C showed a TTS~2~ that was significantly lower than both group A (p = 0.023 at t test) and Group B (p = 0.035 at *t* test).

![Mean TTS2 for the three groups.](0392-100X-32-380-g001){#F1}

Pre-exposure TEOAEs amplitude and repeatability was not significantly different between the three groups. Noise exposure determined a reduction in the amplitude of TEOAE for both group A and B, and no changes in group C. Statistical analysis showed that TEOAE amplitude change after noise exposure was lower for group C compared to Group A (p = 0.089 at *t* test) and group B (p = 0.03 at *t* test).

Discussion {#S4}
==========

The results of the present study show that a 10 day course, and not a single administration, of 600 mg of ALA can protect the cochlea from subsequent acoustic trauma. The protection was evident on both subjective (TTS2 at 6 kHz) and objective (TEAOEs) measures of hearing. In reality, an increased sensitivity of OAEs compared to pure tone audiometry in the monitoring of preclinical cochlear damage, has been demonstrated in literature [@R29] [@R36] [@R37].

Acoustic overstimulation is associated with increased oxidative stress due to ischaemia reperfusion, glutamate excitotoxicity and an increase in mitochondrial free radical production [@R12]^-^[@R15]. ALA, an essential cofactor in mitochondrial enzymes, may protect against cochlear damage through a variety of mechanisms, such as providing a substrate for cochlear GSH synthesis, free radical scavenging and inhibition of cell death pathway activation [@R38].

ALA is readily absorbed from the diet, transported, taken up by cells and reduced to dihydrolipoate in various tissues, including the brain [@R38]. Both lipoate and dihydrolipoate are antioxidants [@R19] and participate in reactions neutralizing RO S as well as in reduction of the oxidized forms of other antioxidants such as endogenous vitamin E, vitamin C and glutathione[@R18]. ALA administration has been shown to increase intracellular glutathione levels by 30-70% both in cell culture and in vivo [@R39], scavenge NO and inhibit the formation of NF-κB (20), a transcription factor whose nuclear transport has recently been shown to increase after acoustic trauma [@R40].

In animal models, ALA has been shown to protect from age-induced and cisplatin-induced hearing loss [@R34] [@R35]. Seidman et al. [@R34] supplemented Fischer rats aged 24 months for 6 weeks with either placebo, acetyl-L-carnitine or ALA. Animals treated with ALA showed a delay in progression of hearing loss, which was, however, significant only at 3 kHz; in addition, qualitative and quantitative analysis of mitochondrial DNA (mt-DNA) showed that in treated animals the common aging deletion was present to a lesser degree [@R34]. Even better results were obtained in rats supplemented with acetyl-L-carnitine. The authors concluded that mitochondrial metabolites such as ALA or acetyl-L-carnitine may reduce age-associated deterioration in auditory sensitivity and improve cochlear function by their ability to protect and repair age-induced mt-DNA damage.

Rybak et al. 35 investigated the protective effect of ALA against cisplatin-induced ototoxicity in Wistar rats, which has been shown to be mediated by RO S. Rats treated with cisplatin plus ALA did not show significant elevations of hearing thresholds, and ALA further prevented the depletion of glutathione as well as the decrease of superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase activities [@R35]. The protective effect of ALA was related to its action as a RO S scavenger and a chelator of platinum from the cochlea. Interestingly, the authors noted that the dose of ALA required to protect from cisplatin toxicity was 3 to 12 times lower than that of other chelating agents.

Animal and human studies have demonstrated that exogenous administration of ALA has therapeutic potential in diabetes and diabetic neuropathy, neurodegenerative disorders and heavy metal toxicity [@R38] [@R41]. In clinical practice, ALA is administered orally at a daily dosage of 600 mg. Although blood levels of lipoate and dihydrolipoate were not dosed in this study, the drug is rapidly absorbed in the stomach, crosses the blood-brain barrier[@R41] and reaches a peak plasma concentration 60 min after oral assumption [@R42].

In the present study, the administration of a single dose of ALA 60 min before acoustic overstimulation did not have any protective effect, while a 10 day course led to significant protection at 6 kHz and on TEOAEs. We believe that the main effect of ALA in these patients is related to an increase in GSH synthesis and free radical scavenging that prevented the TTS.

To date, very few clinical studies have examined the protective effects of compounds in NIHL in humans. Attias et al. [@R08] have shown that the oral assumption of 122 mg of magnesium for 10 days can significantly reduce the TTS induced by a 90 dB SL white noise in normal subjects.

A recent study looked at the protective effects of N-acetylcysteine (NAC), a drug commonly used in clinical practice on TTS in voluntary discotheque attendees [@R43]; an oral dose of 900 mg of NAC or placebo were administered 1 hour prior to attending a local discotheque. Upon exiting, audiometric measures were performed in a soundproof van, and no difference was found between the drug and placebo. Confounding factors in this study were the small number of subjects and the variability in noise exposure levels, and that only one dose of NAC was administered.

More favourable preliminary results have been reported by Kopke et al. [@R09] in military subjects who were supplemented with 2.7 gm/day of NAC, a dose three times higher than that used in discotheque attendees.

In this preliminary study, ALA appears to be protective for the ear from noise in humans. The dosage needed to obtain a protective effect is not higher than that proposed in clinical practice, and therefore ALA seems to have the characteristics of the \"ideal\" pharmacologic prophylaxis. In fact, it specifically addresses known mechanisms of acoustic trauma, is orally administered and is safe, effective and inexpensive [@R09]. Further research is however warranted to evaluate the effects of ALA in a larger study population and its effects on TTS and permanent cochlear damage.
